Forte Biosciences Inc Cash Flow-to-Debt Ratio
Forte Biosciences Inc cash flow-to-debt ratio. Forte Biosciences Inc (FBRX) has a Cash Flow-to-Debt Ratio of -1.08x as of September 2025, meaning its operating cash flow of $-14.00 Million could theoretically repay -1% of its total liabilities ($12.99 Million) in one year. See Forte Biosciences Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Forte Biosciences Inc (2015–2024)
Cash flow-to-debt ratio of Forte Biosciences Inc from 2015 to 2024. Historical debt coverage capacity for Forte Biosciences Inc across 10 annual periods. Also explore Forte Biosciences Inc (FBRX) net asset momentum to track the company's year-over-year net asset growth rate.
Forte Biosciences Inc Cash Flow-to-Debt Ratio by Year (2015–2024)
Forte Biosciences Inc cash flow-to-debt ratio by year from 2015 to 2024. Year-by-year debt coverage analysis for Forte Biosciences Inc. For the full cash flow conversion analysis, see Forte Biosciences Inc (FBRX) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.39x | $-30.75 Million | $9.08 Million | ▲ +56.8% |
| 2023 | -7.83x | $-28.71 Million | $3.67 Million | ▼ -204.1% |
| 2022 | -2.57x | $-8.19 Million | $3.18 Million | ▲ +72.9% |
| 2021 | -9.49x | $-16.68 Million | $1.76 Million | ▼ -16.3% |
| 2020 | -8.16x | $-18.42 Million | $2.26 Million | ▼ -462.7% |
| 2019 | -1.45x | $-2.77 Million | $1.91 Million | ▼ -88.9% |
| 2018 | -0.77x | $-34.47 Million | $44.94 Million | ▲ +48.3% |
| 2017 | -1.48x | $-31.13 Million | $20.99 Million | ▼ -42.4% |
| 2016 | -1.04x | $-29.54 Million | $28.36 Million | ▼ -14.3% |
| 2015 | -0.91x | $-21.04 Million | $23.09 Million | — |